Clinical Trial Update: Comparative Pharmacokinetic Trial of RGB-03 and MabThera [Phase 1]

View source ↗

Summary

This document describes a Phase 1 comparative pharmacokinetic trial of RGB-03 and MabThera (rituximab) in rheumatoid arthritis. The status is listed as UNKNOWN.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Rheumatoid Arthritis

Drugs mentioned

• MabThera (rituximab)
• RGB-03

Snippet

Sponsor: Gedeon Richter Plc. | Conditions: Rheumatoid Arthritis | Phase 1 | Status: UNKNOWN